Drugs that increase intelligence?: Application for childhood cognitive impairment

Mental Retardation and Developmental Disabilities Research Reviews

Volumn 4, Issue 1, 1998, Pages 36-49

  Capone, George T ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acetylcholine precursors; Acetylcholinesterase inhibitors; Alzheimer's disease; Ampakines; Drug therapy; Glycinergics; Mental retardation; Muscarinic agonists; Nootropics

Indexed keywords

ACETYLCHOLINE; ACETYLCHOLINESTERASE; CHOLINERGIC RECEPTOR; GLYCINE RECEPTOR; MUSCARINIC AGENT; NOOTROPIC AGENT; TACRINE;

ALZHEIMER DISEASE; BRAIN CORTEX; CHILD; CHOLINERGIC TRANSMISSION; COGNITIVE DEFECT; DEMOGRAPHY; ENZYME INHIBITION; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPOTHESIS; INTELLIGENCE; MENTAL DEFICIENCY; PRIORITY JOURNAL; REVIEW; SYNAPTIC MEMBRANE;

EID: 0031887455     PISSN: 10804013     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2779(1998)4:1<36::AID-MRDD7>3.0.CO;2-V     Document Type: Review

References (165)

1. Ackerman P, Dykman R, Holloway C, et al. A trial of piracetam in two subgroups of students with dyslexia enrolled in summer tutoring. J Learn Dis 1991;24:542-549.
2. Ahlin A, Adern A, Junthe T, et al. Pharmacokinetics of tetrahydroaminoacrine: Relations to clinical and biochemical effects in Alzheimer's patients. Int Clin Psychopharmacol 1992;7: 29-36.
3. Auteri A, Mosca A, Lattuada N, et al. Pharmacodynamics and pharmacokinetics of eptastigmine in elderly subjects. Eur J Clin Pharmacol 1993;45:373-376.
4. Bachman E, Berger-Sweeney J, Coyle J, et al. Developmental regulation of adult cortical morphology and behavior: An animal model for mental retardation. Int J Dev Neurosci 1994;12:239-253.
5. Barria A, Muller D, Derkach V, et al. Regulatory phosphorylation of AMPA-type glutamate receptors by CaM-KII during long-term potentiation. Science 1997;276:2042-2045.
6. Bartus R, Dean R, Sherman K, et al. Profound effect of combining choline and piracetam on memory enhancement and cholinergic function in aged rats. Neurobiol Aging 1981;2:105-111
7. Becker LE, Armstrong DL, Chan F. Dendritic atrophy in children with Down's syndrome. Ann Neurol 1986;20:520-526.
8. Bekkers J, Stevens C. Presynaptic mechanism for long-term potentiation in the hippocampus. Nature 1990;346:724-729.
9. Benowitz L, Routtenberg A. GAP-43: An intrinsic determinant of neuronal development and plasticity TINS 1997;20:84-91.
10. Binet A, Simon T. L'Annee psychologique. Mason, Paris. Vol. 2, 1905.
11. Bliss T, Collinridge G. A synaptic model of memory: Long-term potentiation in the hippocampus. Nature 1993;361:31-39.
12. Bodick N, Offen W, Levey A, et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive fonction and behavioral symptoms in Alzheirner's disease. Arch Neurol 1997;54:465-473.
13. Bottini G, Vallar G, Cappa S, et al. Oxiracetam in dementia: A double-blind, placebo-controlled study Acta Neurol Scand 1992;86:237-241.
14. Bourgeois J, Jasterboff P, Rakic P. Synaptogenesis in visual cortex of normal and preterm monkeys: Evidence for intrinsic regulation of synaptic overproduction. Proc Natl Acad Sci USA 1989;86:4297-4301.
15. Brown T, Chapman P, Kairiss E, et al. Long-term synaptic potentiation. Science 1988;242:724-728.
16. Cabelli R, Hohn A, Shatz C. Inhibition of ocular dominance column formation by infusion of NT-4/5 or BDNF. Science 1995;267:1662-1666.
17. Calvani M, Carta A. Clues to the mechanism of action of acetyl-L-carnitine in the central nervous system. Dementia 1991;2:1-6.
18. Camp-Bruno J, Herting R. Cognitive effects of milacemide and methylphenidate in healthy young adults. Psychopharmacology 1994;115: 46-52.
19. Carta A, Calvani M, Bravi D, et al. Acetyl-L-Carnitine and Alzheimer's disease: Pharmacological considerations beyond the cholinergic sphere. Ann NY Acad Sci 1993;695:324-326.
20. Chang F, Greenough W. Transient and enduring morphological correlates of synaptic activity and efficacy change in the rat hippocampal slice. Brain Res 1984;309:35-46.
21. Chiarenza G, Ragaini C, Cazzullo A. The acute and chronic administration of piracetam affect the movement-related brain macropotentials. Int J Psychophysiol 1990;8:223-234.
22. Choi D. Calcium: Still center-stage in hypoxicischemic neuronal death. TINS 1995;18: 58-60.
23. Cohen E, Wurtman R. Brain acetylcholine: Control by dietary choline. Science 1976;191:561-562.
24. Cole A, Saffen D, Baraban J, et al. Rapid increase of an immediate-early gene messenger RNA in hippocampal neurons by synaptic NMDA receptor activation. Nature 1989;340-474-476.
25. Comery T, Harris J, Willems P, et al. Abnounal dendritic spines in fragile x knock out mice: Maturation and pruning deficits. Proc Natl Acad Sci USA 1997;94:5401-5404.
26. Connors K, Reader M, Reiss A, et al The effects of piracetam upon visual event-related potentials in dyslexic children. Psychophysiology 1987; 24:513-521.
27. Cooper JR, Bloom FE, Roth RH. The Biochemical Basis of Neuropharmacology. 6th ed New York. Oxford University Press, 1991.
28. Cotman CW, Monaghan DT, Ottersen OP, et al. Anatomical organization of excitatory ammoacid receptors and their pathways. TINS 1987;10:273-279.
29. Crick F. Do dendritic spines twitch? Trends Neurosci 1982;5:44-46.
30. Croisile B, Trillet M, Fondarai J, et al. Long-term and high-dose piracetam treatment of Alzheimer's disease. Neurology 1993;43:301-305.
31. Cummings J, Gorman D, Shapira J. Physostigmine ameliorates the delusions of Alzheimer's disease. Biol Psychiatry 1993;33:536-541.
32. Cutler N, Fakouhi T, Smith W, et al. Evaluation of multiple doses of milacemide in the treatment of senile dementia of the Alzheimer's type. J Geriatr Psych Neurol 1993;6:115-119.
33. Davous P, Lamour L. Bethanacol decreases reaction time in semle dementia of the Alzheimer type. J Neurol Neurosurg Psychiatry 1985;48:1297-1299.
34. de la Morena E. Efficacy of CDP-choline in the treatment of senile alterations in memory. Ann NY Acad Sci 1991;640:233-237.
35. Drachman D. Memory and cognitive function in man: Does the cholinergic system have a specific role? Neurology 1977;27:783-790.
36. Drachman D, Leavitt. Human memory and the cholinergic system. A relationship to aging? Arch Neurol 1974;30:113-121.
37. Drachman D, Glosser G, Fleming P, et al. Memory decline in the aged: Treatment with lecithin and physostigmine. Neurology 1982;32:944-950.
38. Eichenbaum H. How does the brain organize memories? Science 1997;277:330-331.
39. Etienne P, Gauthier S, Dastoor D, et al. Lecithin in Alzheimer's disease. Lancet 1978;1:206.
40. Fagg GE, Foster AC. Amino acid neurotransmitters and their pathways in the mammalian central nervous system. Neuroscience 1983;9:701-719.
41. Farlow M, Gracon S, Hershey L, et al. A controlled trial of tacrine in Alzheimer's disease. JAMA 1992;268:2523-2529.
42. Ferris S, Reisberg B, Friedman E, et al. Combination choline/piracetam treatment of senile dementia. 1982;18:94-98.
43. Fialho J. Dromia and piracetam: A useful association in the treatment of Down syndrome. Presented at the International Symposium on Nootropic Drugs, Rio de Janeiro, 1979.
44. Fifkova E. Long-lasting morphological changes in dendritic spines of dentate granular cells following stimulation of the entorhinal area. J Neurocytol 1977;6:211-230.
45. Fifkova E, Morales M. Calcium-regulated contractile and cytoskeletal proteins in dendritic spines may control synaptic plasticity. Ann NY Acad Sci 1989;568:131-137.
46. Fisher A, Heldman E, Gurwitz D, et al. M1 agonists for the treatment of Alzheimer's disease. Novel properties and clinical update. Ann NY Acad Sci 1996;777:189-196.
47. Fox K, Schlaggar B, Glazewski S, et al. Glutamate receptor blockade at cortical synapses disrupts development of thalamocortical and columnar organization in somatosensory cortex. Proc Natl Acad Sci USA 1996,93:5584-5589.
48. Gamble E, Koch C. The dynamics of free calcium in dendritic spines in response to repetitive synaptic input. Science 1987;236:1311-1315.
49. Garner C, Tucker R, Matus A. Selective localisation of messenger RNA for cytoskeletal protein MAP-2 in dendrites. Nature 1988;336: 674-677.
50. Ghosh A, Greenberg M. Calcium signaling in neurons. Molecular mechanisms and cellular consequences. Science 1995;268.239-247.
51. Goa K, Brogden R. L-Carnitine: A preliminary review of its pharmacokinetics, and its therapeutic use in ischemic cardiac disease and primary and secondary carnitine deficiencies in relationship to its role m fatty acid metabolism. Drug Eval 1987;34:1-24.
52. Goff D, Guochuan T, Manoach D, et al. Dose-finding trial of D-cycloscnne added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry 1995;152:1213-1215.
53. Goff D, Guochuan T, Manoach D, et al. D-cycloserine added to clozapine for patients with schizophrenia. AmJ Psychiatry 1996;153: 1628-1630.
54. Goldman-Rakic P. Working memory and the mind. Sci Am 1992;111-117.
55. Gouhaev A, Senning A. Piracetam and other structurally related nootropics Br Res Rev 1994;19:180-222.
56. Greenmayre J, Porter R. Anatomy and physiology of glutamate in the CNS. Neurology 1994; 44(Suppl 8):7-13.
57. Growdon J, Corkin S, Huff F, et al. Piracetarn combined with lecithin in the treatment of Alzheimer's disease. 1986;7:269-276.
58. Gu Q, Singer W. The role of muscarinic acetylcholine receptors in ocular dominance plasticity. Eur J Neurosci 1993;5:475-485.
59. Halpin S, Greengard P. Activation of NMDA receptors induces rapid dephosphorylation of the cytoskeletal protein MAP-2. Neuron 1990;5:237-246.
60. Hartvig P, Askmark H, Aquilonius S, et al. Clinical pharmacokinetics of intravenous and oral 9-amino-1,2,3,4,-tetrahydroacridine, tacrine. EurJ Clin Pharmacol 1990;38:259-263.
61. Hasselmo M, Bower J. Acetylcholine and memory. TINS 1993;16:218-222.
62. Heiss W, Hebold I, Klinkhammer P, et al. Effects of piracetam on cerebral glucose metabolism in Alzheimer's disease as measured by positron emission tomography. J Cereb Blood Flow Metab 1988;8:613-617.
63. Heresco-Levy U, Silipo G, Javitt D. Glycinergic augmentation of NMDA receptor-mediated neurotransmission in the treatment of schizophrenia. Psychopharmacol Bull 1996;32:731-740.
64. Herting R. Milacemide and other drugs active at glutamate NMDA receptors as potential treatment for dementia. Ann Ny Acad Sci 1991;640:237-240.
65. Hestrin S. Activation and sensitization of glutamate-activated channels mediating fast excitatory synaptic currents in the visual cortex. Neuron 1992;9:991-999.
66. Hohmann C, Berger-Sweeney J (1997): Cholinergic regulation of cortical development and plasticity. Perspect Dev Neurobiol 1997; in press.
67. Hohmann C, Brooks A, Coyle J. Neonatal lesions of the basal forebrain cholinergic neurons result in abnormal cortical development. Dev Brain Res 1988;42:253-264.
68. Hohmann C, Kwiterovich K, Oster-Granitc M, et al. Newborn basal forebrain lesions disrupt cortical cytodifferentiation as visualized by rapid golgi staining. Cereb Cortex 1991;1:143-157.
69. Holmes W. Is the function of dendritic spines to concentrate calcium? Brain Res 1990;519:338-342.
70. Huerta P, Lisman J. Heightened synaptic plasticity of hippocampal CA1 neurons during a cholinergically induced rhythmic state. Nature 1993;364:723-725.
71. Huerta P, Lisman J. Bidirectional synaptic plasticity induced by a single burst during cholinergic theta oscillation in CA1 in vitro. Neuron 1995;15:1053-1063.
72. Huttenlocher P. Synaptic density in human frontal cortex - Developmental changes and effects of aging. Brain Res 1979;163:195-205.
73. Huttenlocher P. Synapse elimination and plasticity in developing human cerebral cortex. Am J Ment Defic 1984;88:488-496.
74. Huttenlocher PR. Dendritic and synaptic pathology in mental retardation. Pediatr Neurol 1991;7:79-85.
75. Hynd G, Willis G. Neurological foundations of intelligence. In: Wolman B, ed. Handbook of Intelligence: Theories, Measurements and Applications. New York: John Wiley, 1985.
76. Imbimbo B, Licini M, Schettino M, et al. Relationship between pharmacokinetics and pharmacodynamics of eptastigmine in young healthy volunteers. J Clin Pharmacol 1995;35: 285-290.
77. Isaac J, Nicoll R, Malenka R. Evidence for silent synapses: Implications for the expression of LTP. Neuron 1995;15:427-434.
78. Javitt D, Zylberman I, Zukin S, et al. Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry 1994;151:1234-1236.
79. Johnson G, Jope R. The role of microtubule-associated protein 2 (MAP-2) in neuronal growth, plasticity and degeneration. J Neuro-sci Res 1992;33:505-512.
80. Johnston M, McKinney M, Coyle J. Evidence for a cholinergic projection to neocortex from neurons in basal forebrain. Proc Natl Acad Sci USA 1979;76:5392-5396.
81. Johnston M, Trescher W, Taylor G. Hypoxic and ischemic central nervous system disorders in infants and children. Adv Pediatr 1995;42: 1-45.
82. Kandel E, O'Dell T. Are adult learning mechanisms also used for development? Science 1992;258: 243-245.
83. Kandel E, Siegelbaum S. Principles underlying electrical and chemical synaptic transmission. In: Kandel E, Schwartz J, eds. Principles of Neural Science. New York: Elsevier, 1985: 979.
84. Kater S, Mills L. Regulation of growth cone behavior by calcium. J Neurosci 1991;11:891-899.
85. Kater S, Mattson M, Guthrie P. Calcium-induced neuronal degeneration: A normal growth cone regulating signal gone awry? Ann NY Acad Sci 1989;568:252-261.
86. Katz L, Shatz C. Synaptic activity and the construction of cortical circuits. Science 1996;274:1133-1138.
87. Kaufman WE, Yamagata K, Andreasson KI, et al. Rapid response genes as markers of cellular signaling during cortical histogenesis: Their potential in understanding mental retardation. Int J Dev Neurosci 1994;12:263-271.
88. Kleinschmidt A, Bear M, Singer W. Blockade of NMDA receptors disrupts experience-dependent plasticity of kitten striate cortex. Science 1987;238:355-358.
89. Knapp M, Knopman D, Solomon P, et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994;271:985-991.
90. Koch C, Zador A, Brown T. Dendritic spines: Convergence of theory and experiment. Science 1992;256:973-974.
91. Krieger D. Brain peptides: What, where and why? Science 1983;222:975-985.
92. Kumar V, Cantillon M. Update on the development of medication for memory and cognition in Alzheimer's disease. 1996;26:280-284.
93. Kunneke P, Malan G. A controlled clinical trial on the effects of piracetam in epileptic children. BrJ Clin Pract 1979,33:266-271.
94. Lauder J. Neurotransmitters as growth regulatory signals: Role of receptors and second messengers. Trends Neurosci 1993;16:233-240.
95. Lawlor B, Davis K. Does modulation of glutamatergic function represent a viable therapeutic strategy in Alzheimer's disease? Biol Psychiatry 1992;31:337-350.
96. Lee C, Benfield P. Aniracetam: An overview of its pharmacodynamic and pharmacokinetic properties and a review of its therapeutic potential in senile cognitive disorders. Drugs Aging 1994;4:257-273.
97. Lehmann D, Wackermann J, Michel C, et al. Space-oriented EEG segmentation reveals changes in brain electric field maps under the influence of a Nootropic drug. Psychiatry Res 1993,50:275-282.
98. Levey A, Kitt C, Simonds W, et al. Identification and localization of acetylcholine receptor proteins in brain with subtype-specific antibodies. J Neurosci 1991;11:3218-3226.
99. Liao D, Hessler N, Malinow R. Activation of postsynaptically silent synapses during pairing-induced LTP in CA1 region of the hippocampal slice. Nature 1995;375:400-404.
100. Little A, Levy R, Chauaqui-Kidd P, et al. A double-blind, placebo controlled trial of high-dose lecithin in Alzheimer's disease. J Neurol Neurosurg Psychiatry 1985;48:736-742.
101. Luria A. The Higher Cortical Functions in Man. New York: Basic Books, 1980.
102. Marin-Padilla M. Pyramidal cell abnormalities in the motor cortex of a child with Downs syndrome. J Comp Neurol 1976;167:63-82.
103. Marx J. Searching for drugs that combat Alzheimer's. Science 1996;273:50-53.
104. Masliah E, Terry R. Role of synaptic pathology in the mechanisms of dementia in Alzheimer's disease. Clin Neurosci 1993;1:192-198.
105. Mattson MP. Neurotransmitters in the regulation of neuronal cytoarchitecture. Brain Res Rev 1988;13.179-212.
106. Mayer M, Miller J. Excitatory amino-acid receptors, second messengers and regulation of intracellular calcium ion in mammalian neurons. TIPS (Special Report) 1991:36-42.
107. McDonald JW, Johnston MV. Physiological and pathophysiological roles of excitatory amino acids during central nervous system development. Brain Res Rev 1990;15:41-70.
108. Mishkin M, Appenzeller T. The anatomy of memory. Sci Am 1987:80-89.
109. Moglia A, Sinforiani E, Zandrini C, et al. Activity of oxiracetam in patients with organic brain syndrome: A neuropsychological study. 1986; 9(Suppl 3):73-78.
110. Monhan J, Handlemann G, Hood W, et al. D-cycloserine, a positive modulator of N-methyl-D-aspartate receptor, enhances performance of learning tasks in rats. Pharmacol Biochem Behav 1989;34:649-653.
111. Murphy D, Segal M. Morphological plasticity of dendritic spines in central neurons is mediated by activation of cAMP response element binding protein. Proc Natl Acad Sci USA 1997;94:1482-1487.
112. Nicoletti F, Casabona G, Ganazzani A, et al. Excitatory amino acids and neuronal plasticity: Modulation of AMPA receptors as a novel substrate for the action of nootropic drugs. Funct Neurol 1992;7:413-422.
113. Nieuwenhuys R. Chemoarchitecture of the Brain. Berlin: Springer-Verlag, 1985.
114. O'Dell T, Hawkins R, Kandel E, et al. Tests of the roles of two diffusible substances in long-term potentiation: Evidence for nitric oxide as a possible early retrograde messenger. Proc Natl Acad Sci USA 1991;88:11285-11289.
115. Page K, Everott B. The distribution of neurons coexpressing immunoreactivity to AMPA-sensitive glutamate receptor subtypes (GluR1-4) and nerve growth factor receptor in the rat basal forebrain. Eur J Neurosci 1995;7:1022-1033.
116. Parnetti L. Clinical pharmacokinetics of drugs for Alzheimer's disease. Drug Dispos 1995;29: 110-129.
117. Perucca F., Albrici A, Gatti G, et al. Pharmacokinetics of oxiracetam following intravenous and oral administration in healthy volunteers. Eur J Drug Metab Pharmacokinet 1984;3:267-274.
118. Pettegrew J, Klunk W, Panchalingam K, et al. Clinical and neurochemical effects of Acetyl-L-Carnitine in Alzheimer's disease. Neurobiol Aging 1995;16:1-4.
119. Poschel B. New pharmacologic perspectives on nootropic drugs. In: Iversen L, Iversen S, Snyder S, eds. Handbook of Psychopharmacology. Vol. 20. New York: Plenum Press, 1988:437-469.
120. Pulsifer M. The neuropsychology of mental retardation. JINS 1996;2:159-176.
121. Rall W. Cellular Mechanisms Subserving Changes in Neuronal Activity. Los Angeles: University of California Press, 1974.
122. Raskind M, Sadowsky C, Sigmund W, et al. Effect of tacrine on language, praxis, and noncognitive behavioral problems in Alzheimer's disease. Arch Neurol 1997;54:836-840.
123. Richardson RT, DeLong MR. A reappraisal of the functions of the nucleus basalis of Meynert. TINS 1988;11:264-267.
124. Rogers S, Fnedhoff L. The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a U.S. multicentre, randomized, double-blind, placebo-controlled trial. Dementia 1996;7:293-303.
125. Rogers S, Yamanishi Y, Yamatsu K. E2020 - The pharmacology of a piperidine cholinesterase inhibitor. In: Becker R, Giacobini E, eds. Cholinergic Basis for Alzheimer Therapy. Boston: Birkhauser, 1991:315-320.
126. Rosse R, Theut S, Banay-Schwartz M, et al Glycine adjuvant therapy to conventional neurolepric treatment in schizophrenia: An open-label, pilot study. Clin Neuropharmacol 1989;12:416-424.
127. Rudel R, Helfgott E. Effect of piracetam on verbal memory of dyslexic boys. J Am Acad Child Psychiatry 1984;23:695-699.
128. Rudelli R, Brown W, Wisnewski K, et al. Adult fragile X syndrome. Acta Neuropathol 1985; 67:289-295.
129. Rupmak N, Tye S, Brazell C, et al. Reversal of cognitive impairment by heptylphysostig-mine, a long-lasting cholinesterase inhibitor, in primates. J Neurol Sci 1992;107:246-249.
130. Rynders J History of Down syndrome. In: Pueschel S, ed. New Perspectives on Down Syndrome. Baltimore: Paul H. Brookes, 1987:1-17.
131. Sano M, Bell K, Cote L, et al. Double-blind parallel design pilot study of acetyl levocarnitine in patients with Alzheimer's disease. Arch Neurol 1992;49:1137-1141.
132. Sano M, Bell K, Marder K, et al. Safety and efficacy of oral physostigmine in the treatment of Alzheimer's disease. Clin Neurophamacol 1993;16:61-69.
133. Schell M, Brady R, Molliver M, et al. D-serine as a neuromodulator: Regional and developmental localizations in rat brain glia resemble NMDA receptors. J Neurosci 1997;17:1604-1615.
134. Schneggenburger R, Tempia F, Konnerth A. Glutamate- and AMPA-mediated calcium influx through glutamate receptor channels in medial septal neurons. Neuropharmacology 1993;32:1221-1228.
135. Schneider L. New therapeutic approaches to Alzheimer's disease. J Clin Psychiatry 1996; 57(Suppl 14):30-36.
136. Schwartz B, Hashtroudi S, Herting R, et al. Glycine prodrug facilitates memory retrieval in humans. Neurology 1991;41:1341-1343.
137. Senin U, Abate G, Fieschi C, et al. Aniracetam in the treatment of senile dementia of Alzheimer type (SDAT): Results of a placcbo controlled, multicentre clinical study. Eur Neuropsychopharmacol 1991;1:511-517.
138. Shennan K. Pharmacodynamics of oral E2020 and tacrine in humans: Novel approaches. In: Becker R, Giacobini E, eds. Cholinergic Basis for Alzheimer Therapy. Boston. Birkhauser, 1991:321-328.
139. Simeon J, Waters B, Resnick M. Effects of piracetam in children with learning disorders. Psychopharmacol Bull 1980;16:65-66.
140. Singer W. Development and plasticity of cortical processing architectures. Science 1995;270: 758-764.
141. Spagnoli A, Lucca U, Menasce G, et al. Long-term acetyl-L-carnitine treatment in Alzheimer's disease. Neurology 1991;41:1726-1732.
142. Spearman C General intelligence: Objectively determined and measured. In: Wiseman S, ed. Intelligence and Ability: Selected Readings. Harmondsworth: Penguin, 1967.
143. Spiers P, Myers D, Hochanadel G, et al. Citicoline improves verbal memory in aging. Arch Neurol 1996;53:441-448.
144. Spitz H. The Raising of Intelligence: A Selected History of Attempts to Raise Retarded Intelligence. Hillsdale: Lawrence Erlbaum Associates, 1986.
145. Sramek J, Hurley D, Wardle T, et al. The safety and tolerance of xanomeline tartrate in patients with Alzheimer's disease. J Clin Pharmacol 1995;35:800-806.
146. Suetsugu M, Mehraein P. Spine distribution along the apical dendrites of the pyramidal neurons in Down's syndrome. Acta Neuropathologica 1980;50:207-210.
147. Svoboda K, Tank D, Denk W. Direct measurement of coupling between dendritic spines and shafts. Science 1996;272:716-719.
148. Takashima S, Iida K, Mito T, et al. Dendritic and histochemical development and ageing in patients with Down syndrome. J Int Dis Res 1994;38:265-273.
149. Taylor H Critical issues and future directions in the development of theories, models, and measurements for attention, memory, and executive function. In: Lyon G, Krasnegor N, eds. Attention, Memory and Executive Function. Baltimore: Paul H. Brookes, 1996:424.
150. Thai L, Lasker B, Sharpless N, et al. Plasma physostigmine concentrations after controlled-release administration. Arch Neurol 1989; 46:13.
151. Thal L, Schwartz G, Sano P, et al. A muliticentre double-blind study of the controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease. Neurology 1996;47:1389-1395.
152. Thoenen H. Neurotrophins and neuronal plasticity. Science 1995;270:593-598.
153. Vernon M, Sorkin E. Piracetam: An overview of its pharmacological properties and a review of its therapeutic use in senile cognitive disorders. Drugs Aging 1991;1:17-35.
154. Villardita C, Grioli S, Lomeo C, et al. Clinical studies with oxiracetam in patients with dementia of the Alzheimer type and multin-farct dementia of mild to moderate degree. Pharmacopsychiatry 1992;25:24-28.
155. Volavka J, Simeon J, Simeon S, et al. Effect of piracetam on EEG spectra of boys with learning disorders. Psychopharmacology 1981; 72:185-188.
156. Vyklicky L, Patneau D, Mayer M Modulation of excitatory synaptic transmission by drugs that reduce desensitization at AMPA/kainate receptors. Neuron 1991;7:971-984.
157. Watkins P, Zimmerman H, Knapp M, et al. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994;271:992-998.
158. Weiss G. Metabolism and actions of CDP-choline as an endogenous compound and administered exogenously as citicoline. Life Sci 1995,56:637-660.
159. Wickelgren I. Getting a grasp on working memory. Science 1997;275:1580-1582.
160. Wilsher C, Atkins G, Manfield P. Piracetam as an aid to learning in dyslexia. Psychopharmacology 1979;65:107-109.
161. Wilsher C, Bennett D, Chase C, et al. Piracetam and dyslexia: Effects on reading tests. J Clin Psychopharmacol 1987;7:230-237.
162. Wu G, Malinow R, Cline H. Maturation of a central glutamatergic synapse. Science 1996; 274:972-976.
163. Wurtman R, Hirsch M, Growdon J. Lecithin consumption raises serum-free-choline levels. Lancet 1977;2:68-69.
164. Wurtman R, Magil S, Reinstein D. Piracetam diminishes hippoeampal acetylcholine levels in rats. Life Sci 1981;28:1091-1093.
165. Zafra F, Hengerer B, Leibrock J, et al. Activity dependent regulation of BDNF and NGF mRNAs in the rat hippocampus is mediated by non-NMDA glutamate receptors. EMBO J 1990;9:3545-3550.